Veraxa Biotech AG
VRXA
Positions held
Your positionsVRXA isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $183.83M | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | -1.01 | Beta | 0.19 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 66.0% | Operating margin | -2826.6% |
| Profit margin | 0.0% | ROE | -8.7% | ROA | -50.0% | Debt / equity | — |
| Current ratio | 0.44 | Free cash flow | $15.75M | Analyst recommendation | none | Mean target | — |
| 52w high | $27.36 | 52w low | $1.04 |
Quarterly
No data yet.
Yearly (6y)
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M |
| Op margin | -282662.7% | — | — |
| Net income | -$66.6M | -$28.1M | -$16.5M |
| Gross margin | 66.0% | — | — |
| Gross profit | $0.0M | $0.0M | — |
| Operating income | -$66.2M | -$28.9M | -$16.7M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · VERAXA Biotech (VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing
2026-10-07 · This Tiny Biotech Stock Is Down 96% This Year. Can Next-Gen Drug Testing Save It?
2026-10-07 · Veraxa Biotech stock gains on FDA-aligned testing strategy
2026-10-07 · VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
2026-09-24 · VERAXA Biotech (VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half Progress
2026-09-22 · VERAXA Biotech (VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase
2026-09-18 · VERAXA Biotech (VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline
2026-09-16 · VERAXA Biotech (VRXA) Building a New Approach to Precision Cancer Therapy
2026-09-09 · VERAXA Biotech Designates Raju Willener as CFO
2026-09-08 · VERAXA Biotech (VRXA) Appoints Raju Willener as Chief Financial Officer
Price (daily)
Full chart · RSI · MACD · patterns